# FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

> **NCT00129389** · PHASE3 · COMPLETED · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 1925 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Fluorouracil
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00129389
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09-19
- **Primary completion:** 2013-10-01
- **Final completion:** 2013-10-01
- **Target enrollment:** 1925 (ACTUAL)
- **Last updated:** 2023-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00129389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00129389, "FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00129389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*